WO2002028857A8 - Polymorphs of pioglitazone hydrochloride and their use as antidiabetics - Google Patents

Polymorphs of pioglitazone hydrochloride and their use as antidiabetics

Info

Publication number
WO2002028857A8
WO2002028857A8 PCT/US2001/029899 US0129899W WO0228857A8 WO 2002028857 A8 WO2002028857 A8 WO 2002028857A8 US 0129899 W US0129899 W US 0129899W WO 0228857 A8 WO0228857 A8 WO 0228857A8
Authority
WO
WIPO (PCT)
Prior art keywords
antidiabetics
polymorphs
pioglitazone hydrochloride
pyridyl
benzyl
Prior art date
Application number
PCT/US2001/029899
Other languages
French (fr)
Other versions
WO2002028857A1 (en
Inventor
Rajender Kumar Potlapally
Ramabhadra Sarma Mamillapalli
Om Reddy Gaddam
Original Assignee
Reddy Research Foundation
Cord Janet I
Rajender Kumar Potlapally
Ramabhadra Sarma Mamillapalli
Om Reddy Gaddam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Research Foundation, Cord Janet I, Rajender Kumar Potlapally, Ramabhadra Sarma Mamillapalli, Om Reddy Gaddam filed Critical Reddy Research Foundation
Priority to AU2001291233A priority Critical patent/AU2001291233A1/en
Publication of WO2002028857A1 publication Critical patent/WO2002028857A1/en
Publication of WO2002028857A8 publication Critical patent/WO2002028857A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel polymorphic/pseudopolymorphic forms of 5-[4-[2-(5-ethyl-2-pyridyl)benzyl]thiazolidine-2,4-dione hydrochloride having formula (I). The invention also relates to a pharmaceutical composition comprising the novel polymorphic forms or its mixture and a pharmacuetically acceptable carrier. The polymorphic forms of th epresent invention ar emore active, as an antidiabetic than the hitherto known 5-[4-[2-(5-ethyl-2-pyridyl)ethoxyl]benzyl]thiazolidene-2,4-dione hydrochloride.
PCT/US2001/029899 2000-10-05 2001-09-25 Polymorphs of pioglitazone hydrochloride and their use as antidiabetics WO2002028857A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001291233A AU2001291233A1 (en) 2000-10-05 2001-09-25 Polymorphs of pioglitazone hydrochloride and their use as antidiabetics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN845/MAS/00 2000-10-05
IN845MA2000 2000-10-05

Publications (2)

Publication Number Publication Date
WO2002028857A1 WO2002028857A1 (en) 2002-04-11
WO2002028857A8 true WO2002028857A8 (en) 2002-09-06

Family

ID=11097189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029899 WO2002028857A1 (en) 2000-10-05 2001-09-25 Polymorphs of pioglitazone hydrochloride and their use as antidiabetics

Country Status (2)

Country Link
AU (1) AU2001291233A1 (en)
WO (1) WO2002028857A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337749A1 (en) 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
US20100222334A1 (en) * 2007-10-09 2010-09-02 Wayne Talamonti Pharmaceutical Formulation of Valsartan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN182496B (en) * 1996-02-20 1999-04-17 Reddy Research Foundation
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds

Also Published As

Publication number Publication date
WO2002028857A1 (en) 2002-04-11
AU2001291233A1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
RS51343B (en) Novel composition and use
DZ3316A1 (en) Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
WO2002026737A8 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
MXPA01010821A (en) Polymorph of 5-[4-[2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
WO2002028857A8 (en) Polymorphs of pioglitazone hydrochloride and their use as antidiabetics
WO2000063205A3 (en) Thiazolidinedione derivative and its use as antidiabetic
SI1315723T1 (en) The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
PT1349855E (en) 5-`4-`2-(n-methyl-n- (2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione mesylate salt
NZ515164A (en) Thiazolidinedione derivative and its use as antidiabetic
AP1814A (en) Tartrate salts of thiazolidinedione derivative.
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
WO2005021542A3 (en) Process for the preparation of pioglitazone
DK1446404T3 (en) Rosiglitazone disylates and their use as antidiabetics
AU2001284274A1 (en) A thiazolidinedione derivative and its use as antidiabetic
MXPA02012100A (en) Thiazolidinedione salt for treatment of diabetes mellitus.
AP1785A (en) Tartrate salt of thiazolidinedione derivative.
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
PL363683A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
HK1068884A1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyleof; and its use as pharmaceutical active ingredie)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thernt
EA200300423A1 (en) TIAZOLIDINDION DERIVATIVE AND ITS APPLICATION AS AN ANTI-DIABETIC MEDICINE
SI1173435T1 (en) Polymorph of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione maleic acid salt
SI1265893T1 (en) Hydrochloride salts of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP